Skip to main content

Tessera Defense & Homeland Security Inc.

HLSQ
Exchange
NYSE
Industry
Services-Prepackaged Software
SEC CIK
0001739174

No open-market purchases or sales by Tessera Defense & Homeland Security Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $237.3K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tessera Defense & Homeland Security Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tessera Defense & Homeland Security Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tessera Defense & Homeland Security Inc.
NameTitleLast reported holdingLast filingFilings, past year
Yeganeh ReuvenDirector, 10% Owner0IndirectMar 18, 20262
Deerfield Management Company, L.P.Director, Other: *Director by Deputization1,247,054IndirectApr 23, 20250
Flynn James EDirector, Other: *Director by Deputization1,247,054IndirectApr 23, 20250
Deerfield Mgmt HIF, L.P.Director, Other: *Director by Deputization1,247,054IndirectApr 23, 20250
Deerfield Healthcare Innovations Fund II, L.P.Director, Other: *Director by Deputization1,247,054IndirectApr 23, 20250
Deerfield Private Design Fund V, L.P.Director, Other: *Director by Deputization1,247,054IndirectApr 23, 20250
Deerfield Mgmt V, L.P.Director, Other: *Director by Deputization1,247,054IndirectApr 23, 20250
Leff Jonathan SDirector–Apr 21, 20250
Williams EddieDirector–Apr 21, 20250
Goodman JesseDirector–Apr 21, 20250
Greig RussellDirector3,750IndirectApr 21, 20250
Blum SusanDirector–Apr 21, 20250
Solomon Jonathan EitanChief Executive Officer126,748Apr 21, 20250
Bassan MeravChief Development Officer79,597Apr 21, 20250
Wolfson MarinaChief Financial Officer68,545Apr 21, 20250
Moses Alan CharlesDirector5,000Apr 21, 20250
Merril Gregory LouisDirector–Apr 21, 20250
Cystic Fibrosis Foundation10% Owner9,330,580Mar 4, 20250
Oron AssafChief Business Officer25,804Sep 18, 20240
Gordon Carl L10% Owner13,773,653IndirectMay 20, 20240
OrbiMed Israel GP Ltd.10% Owner13,773,653IndirectMay 20, 20240
OrbiMed Israel BioFund GP Limited Partnership10% Owner13,773,653IndirectMay 20, 20240
Chimovits Erez10% Owner13,773,653IndirectMay 20, 20240
Marks Jason M.Director–Aug 23, 20230
Dambach Michael E.Director–Aug 23, 20230
Sullivan Lynne MarieDirector12,500Mar 3, 20230
Ugwumba ChidozieOther: Exit Form 4 - former 10% owner2,997,025IndirectNov 14, 20220
Grossman JonasDirector372,717Mar 31, 20220
Amusa GbolahanDirector262,871Mar 31, 20220
Walton Thomas Layton10% Owner0IndirectFeb 14, 20220
Sekhri Paul JDirector12,500Jul 30, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 18, 2026 (view filing)Mar 16-172 daysYeganeh ReuvenDirector, 10% OwnerSSaleCommon Stock, $0.0001 par value per share−980.0K$5.00−$4.90M−100.0%0 after2 lots
Mar 18, 2026 (view filing)Mar 162 daysYeganeh ReuvenDirector, 10% OwnerSSale−3.30M$7.60−$25.1M–0 afterDerivative3 lots
Mar 13, 2026 (view filing)Mar 12-131 dayYeganeh ReuvenDirector, 10% OwnerSSaleCommon Stock, $0.0001 par value per share−670.0K$5.00−$3.35M−100.0%0 after2 lots
May 20, 2024 (view filing)4:39 PM ETMay 155 daysLateGordon Carl L and 3 others10% OwnerSSale−24.3K$0.3812−$9.28K−0.2%13.8M after
Mar 19, 2024 (view filing)9:06 PM ETMar 154 daysGordon Carl L and 3 others10% OwnerPPurchase+6.49M–––2.16M afterDerivative2 lots
Dec 1, 2023 (view filing)4:46 PM ETNov 292 daysOron AssafChief Business OfficerSSale−10.9K$0.3731−$4.07K−100.0%0 after3 lots
May 24, 2023 (view filing)6:03 AM ETMay 222 daysOron AssafChief Business OfficerPPurchase+3.19K$0.2731+$871.74+41.3%10.9K after
May 22, 2023 (view filing)4:01 PM ETMay 18-194 daysOron AssafChief Business OfficerPPurchase+7.72K$0.2796+$2.16KNew position7.72K after2 lots
Mar 17, 2023 (view filing)4:29 PM ETFeb 2718 daysLateGordon Carl L and 3 others10% OwnerPPurchase+348.0K$0.245+$85.3K+12.4%3.16M after
Mar 17, 2023 (view filing)4:29 PM ETFeb 2718 daysLateGordon Carl L and 3 others10% OwnerPPurchase+1.79M–––1.79M afterDerivative
Nov 14, 2022 (view filing)6:37 PM ETOct 17-Nov 428 daysLateUgwumba ChidozieOther: Exit Form 4 - former 10% ownerSSale−75.0K$0.3549−$26.6K−2.4%3.00M after15 lots
Nov 14, 2022 (view filing)6:17 PM ETSep 16-Oct 1459 daysLateUgwumba ChidozieOther: Exit Form 4 - former 10% ownerSSale−277.2K$0.3868−$107.2K−8.3%3.07M after21 lots
Nov 14, 2022 (view filing)Aug 10-Sep 1596 daysLateUgwumba ChidozieOther: Exit Form 4 - former 10% ownerSSale−288.6K$0.6399−$184.7K−7.9%3.35M after26 lots
Aug 17, 2021 (view filing)Jul 2622 daysGrossman JonasDirectorPPurchaseCommon Stock, par value $0.0001+37.5K––+11.2%372.7K afterAmended
Aug 17, 2021 (view filing)Jul 26, 2020387 daysGrossman JonasDirectorPPurchase+28.1K–––28.1K afterAmendedDerivative
Jul 30, 2021 (view filing)6:20 PM ETJul 282 daysOrbiMed Israel GP Ltd. and 1 other10% OwnerPPurchaseCommon Stock, $0.0001 par value+500.0K––+21.6%2.81M after
Jul 30, 2021 (view filing)6:20 PM ETJul 282 daysOrbiMed Israel GP Ltd. and 1 other10% OwnerPPurchase+375.0K–––375.0K afterDerivative
Jul 30, 2021 (view filing)Jul 282 daysWolfson MarinaSVP of Finance & OperationsPPurchase+3.75K$4.00+$15.0KNew position3.75K afterDuplicate filing
Jul 30, 2021 (view filing)Jul 282 daysWolfson MarinaSVP of Finance & OperationsPPurchase+2.81K–––2.81K afterDerivativeDuplicate filing
Jul 30, 2021 (view filing)Jul 282 daysSullivan Lynne MarieDirectorPPurchase+12.5K$4.00+$50.0KNew position12.5K after
Jul 30, 2021 (view filing)Jul 282 daysSullivan Lynne MarieDirectorPPurchase+9.38K–––9.38K afterDerivative
Jul 30, 2021 (view filing)Jul 282 daysSolomon Jonathan EitanChief Executive OfficerPPurchase+25.0K$4.00+$100.0KNew position25.0K after
Jul 30, 2021 (view filing)Jul 282 daysSolomon Jonathan EitanChief Executive OfficerPPurchase+18.8K–––18.8K afterDerivative
Jul 30, 2021 (view filing)Jul 282 daysGreig RussellDirectorPPurchase+3.75K$4.00+$15.0KNew position3.75K after
Jul 30, 2021 (view filing)Jul 282 daysGreig RussellDirectorPPurchase+2.81K–––2.81K afterDerivative
Jul 30, 2021 (view filing)Jul 282 daysSekhri Paul JDirectorPPurchase+12.5K$4.00+$50.0KNew position12.5K after
Jul 30, 2021 (view filing)Jul 282 daysSekhri Paul JDirectorPPurchase+9.38K–––9.38K afterDerivative
Jul 30, 2021 (view filing)Jul 282 daysMoses Alan CharlesDirectorPPurchase+5.00K$4.00+$20.0KNew position5.00K after
Jul 30, 2021 (view filing)Jul 282 daysMoses Alan CharlesDirectorPPurchase+3.75K–––3.75K afterDerivative
Jul 28, 2021 (view filing)Jul 262 daysAmusa GbolahanDirectorPPurchaseCommon Stock, par value $0.0001+25.0K––+10.5%262.9K after
Jul 28, 2021 (view filing)Jul 262 daysAmusa GbolahanDirectorPPurchase+18.8K–––18.8K afterDerivative